JP Morgan Downgrades Enfusion: Here's What You Need To Know

Enfusion, Inc. +0.97%

Enfusion, Inc.




JP Morgan downgraded its rating of Enfusion (NYSE:ENFN) to Underweight with a price target of $9.00, changing its price target from $11.00 to $9.00.

Shares of Enfusion are trading down 3.65% over the last 24 hours, at $8.19 per share.

A move to $9.00 would account for a 9.89% increase from the current share price.

About Enfusion

Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via